Popular Articles

Today's Opinions And Editorials
A Better Remedy For Health Reform The Dallas Morning News
generic viagra online
FoldRx Pharmaceuticals Announces Positive Results From Pivotal Phase II/III Clinical Study Of Tafamidis
FoldRx Pharmaceuticals, Inc. (FoldRx) announced positive results from its pivotal Phase II/III clinical study of the company"s lead compound, tafamidis (Fx-1006A), in patients suffering from TTR amyloid polyneuropathy (ATTR-PN), a fatal orphan disease also known as Familial Amyloid Polyneuropathy (FAP). Liver transplantation is the only currently available treatment option for this progressive neurodegenerative disease. Preliminary results from the first randomized controlled trial ever completed in this disease demonstrate that tafamidis treatment significantly halts disease progression in ATTR-PN, reduces the burden of disease after 18 months compared to placebo, and appears to be safe and well-tolerated.
News of the day
AEterna Zentaris To Report Data From Safety Study Of Phase 3 Program In Benign Prostatic Hyperplasia With Cetrorelix Ahead Of Schedule
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is scheduled to be completed at the end of this week. Therefore, data analysis and reporting will be brought forward from the scheduled fourth quarter into the third quarter of 2009, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone.
Diagnostics

Massachusetts Proposal To End Fee-For-Service Could Be National Model

A proposal in Massachusetts to end the practice of paying doctors for individual procedures could prove a model to hold down costs for U.S. health care reform, Reuters reports. "A state-appointed panel of experts has endorsed the proposed "global payment system," which would make Massachusetts the first state in the nation to end the practice of paying healthcare providers for individual procedures. The proposed system instead attaches a fixed price to the routine healthcare costs incurred by a patient for a given time period, such as a year." A special commission in Massachusetts endorsed the idea last week. The state provides near-universal coverage and has often been used as a "template for revamping the national healthcare system," Reuters reports. "Advocates see the Massachusetts idea, which has yet to be included in legislation, as a way to curb costs, but they also are concerned about how long it would take to realize those savings. Proponents say it will eliminate unnecessary medical procedures that the current system encourages by paying doctors for each test or treatment they administer. Requiring doctors to treat patients under a set-fee system would give them a financial incentive to not perform unneeded treatments or tests, the panel said. ò€¦ Under the Massachusetts proposal, healthcare providers and insurance companies would create a common system for evaluating quality of care and setting budgets." Insurers would set a budget for doctors who would receive a portion of the savings if they come under budget. Insurers and employers would do the same if the amount spent on care came in under budget. "Critics say that unanticipated patient healthcare costs could pose a huge financial burden on doctors and hospitals. They have also expressed fear that the budget structure of the global payment system would limit patient access to care, but Nicholas said that problem would be managed in a similar manner to the current system" (Kutz, 7/21). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):